logo-loader

ImmuPharma says Lupuzor trial in 'new territory' and on schedule

Published: 02:41 17 May 2017 EDT

picture of lupus symptons
Lupus is an auto-immune disease

ImmuPharma PLC (LON:IMM) is on schedule to publish first results from its phase III trial of lupus drug Lupuzor early next year with all 200 patients now having had at least three months worth of treatment.

The trial runs for twelve months and 28 patients have now received the full dosage, Immupharma said, while 166 are passed six months. 

Tim McCarthy, chairman, said:We are now in important new territory with over 80% of patients having had exposure to Lupuzor for over six months, compared to our Phase IIb three month study, whilst still maintaining an excellent safety profile."

WATCH: Lupuzor safety profile 'holding up', says ImmuPharma boss

He added Immupharma would provide further updates from the study as it progresses through 2017.

Lupus (Systemic Lupus Erythematosus) is a chronic, potentially life-threatening auto-immune disease. Lupuzor affects the body's immune system so that it does not attack healthy cells and can halt the progression of the disease .

The drug has been granted Fast Track status by US regulator, the FDA, with the Phase III given leeway for fewer pateints than normal to be treated due to the strong safety and efficacy profile.

Of the 200 patients in the trial, 70 are in the US, 81 in Europe and 49 in Mauritius.

ImmuPharma "absolutely delighted" to push on with new clinical trial

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that the specialty biopharmaceutical will be moving forward into a key phase 2/3 adaptive clinical trial, alongside its US partners Avion...

on 06/27/2023